Zacks Investment Research downgraded shares of Corium International (NASDAQ:CORI) from a hold rating to a sell rating in a research report released on Thursday morning.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
A number of other research analysts have also weighed in on the company. Cantor Fitzgerald reissued a buy rating and issued a $14.00 price objective on shares of Corium International in a report on Tuesday, March 27th. ValuEngine raised Corium International from a sell rating to a hold rating in a report on Friday, February 2nd. BidaskClub lowered Corium International from a buy rating to a hold rating in a report on Saturday, February 3rd. Finally, HC Wainwright set a $14.00 target price on Corium International and gave the stock a buy rating in a report on Friday, February 9th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company. Corium International currently has a consensus rating of Buy and a consensus target price of $13.00.
Shares of Corium International opened at $8.93 on Thursday, MarketBeat.com reports. The company has a debt-to-equity ratio of 1.89, a current ratio of 8.11 and a quick ratio of 7.95. Corium International has a fifty-two week low of $6.25 and a fifty-two week high of $13.93.
Corium International (NASDAQ:CORI) last announced its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). The firm had revenue of $10.06 million during the quarter, compared to analyst estimates of $7.07 million. Corium International had a negative net margin of 156.05% and a negative return on equity of 273.01%. sell-side analysts predict that Corium International will post -1.53 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. grew its holdings in Corium International by 115.3% during the first quarter. Franklin Resources Inc. now owns 2,059,175 shares of the biopharmaceutical company’s stock worth $23,618,000 after acquiring an additional 1,102,910 shares during the period. BlackRock Inc. grew its holdings in Corium International by 11.9% during the first quarter. BlackRock Inc. now owns 1,880,505 shares of the biopharmaceutical company’s stock worth $21,569,000 after acquiring an additional 200,690 shares during the period. RTW Investments LP grew its holdings in Corium International by 1.4% during the fourth quarter. RTW Investments LP now owns 1,699,653 shares of the biopharmaceutical company’s stock worth $16,334,000 after acquiring an additional 24,174 shares during the period. Tamarack Advisers LP grew its holdings in Corium International by 9.4% in the first quarter. Tamarack Advisers LP now owns 1,105,000 shares of the biopharmaceutical company’s stock valued at $12,674,000 after purchasing an additional 95,000 shares during the period. Finally, Opaleye Management Inc. grew its holdings in Corium International by 15.2% in the fourth quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock valued at $10,186,000 after purchasing an additional 140,000 shares during the period. 95.13% of the stock is currently owned by hedge funds and other institutional investors.
About Corium International
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.